Koszalin

Poland

107 total trials 49 recruiting

Filter these 107 trials by phase, condition, sponsor and more.

Open in Search →

7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended

2023-505284-36-00 4 2021-09-13 Advanced solid tumors
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C … Ended

2023-505698-34-00 4 2021-07-13 Hepatocellular carcinoma
Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended

2023-506932-33-00 4 2020-10-20 non-small cell lung cancer
Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended

2023-506933-32-00 4 2020-10-20 Non-small Cell Lung Cancer (NSCLC)
Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended

2023-506934-56-00 4 2020-10-20 Non-small Cell Lung Cancer
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended

2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended

2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended

2023-504963-17-00 9 Advanced ccRCC
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended

2023-506975-83-00 5 HER2-positive metastatic breast cancer (MBC) and early breast cancer (

Showing 97–107 of 107 trials